Effect of Fermented Ginseng (GINST) on Sperm Motility
Launched by JAE HOON LEE · Jun 9, 2017
Trial Information
Current as of August 19, 2025
Unknown status
Keywords
ClinConnect Summary
This multicenter, randomized, double-blind, placebo-controlled clinical trial was aimed to evaluate of sperm motility improvement effect of fermented ginseng(GINST). Experimental arm and control arm were randomly assigned among the volunteers who met the inclusion criteria: men between the ages of 18 and 60 who had sperm motility of less than 32%.
To experimental arm, capsules including 160mg of fermented ginseng(GINST) ingredients will be provided for 12 weeks. To control arm, capsules of the same shape and weight as GINST capsules will be provided. These capsules are made of a cellulose ...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Male between 18 and 60 years old
- • Men who have agreed to participate in this trial before the start of the study and who have written an informed consent
- Exclusion Criteria:
- • Those who are diagnosed and treated for hypertension (systolic blood pressure\> 140mmHg and diastolic blood pressure\> 90mmHg)
- • Patients with a history of chemotherapy for malignant tumors
- • Patients with a history of taking testosterone or antiandrogens within 1 month
- • BMI\> 30 or BMI \<18
- • Those who have the following results in the blood test: AST(aspartate aminotransferase ), ALT(Alanine transaminase) \> 2 times the upper limit of reference range; Serum Creatinine\> 2.0 mg / dl
- • Those who ingested drugs (eg, folic acid, L-carn, HCG(human chorionic gonadotropin ), FSH(Follicle-stimulating hormone), Clomiphene, etc.) that have an effect on sperm motility within 2 weeks before the screening day.
- • Persons who have received antipsychotic medication within 2 months before the screening test
- • Those who have history of alcoholism or substance abuse
About Jae Hoon Lee
Jae Hoon Lee is an esteemed clinical trial sponsor known for his commitment to advancing medical research and improving patient outcomes. With a robust background in clinical development and a focus on innovative therapeutic solutions, he leads initiatives that prioritize rigorous scientific methodology and ethical standards. His collaborative approach fosters partnerships with healthcare professionals and research institutions, ensuring the successful execution of trials while adhering to regulatory guidelines. Jae Hoon Lee's expertise and dedication contribute significantly to the advancement of healthcare solutions that address critical unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Wŏnju, Gangwondo, Korea, Republic Of
Incheon, , Korea, Republic Of
Patients applied
Trial Officials
Young Sik Choi, M.D., Ph.D.
Study Director
Severance Hospital, Yonsei University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials